BioSpace News Archive

Aptose Biosciences Inc. announced that clinical data for HM43239, a myeloid kinome inhibitor in-licensed by Aptose is being presented in an oral presentation at the 63rd American Society of Hematology Annual Meeting and Exposition, being held Saturday, December 11 – Monday, December 14, 2021 in Atlanta, GA and virtually.

Vincerx Pharma, Inc., a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, announced that two abstracts related to the Company’s selective PTEFb/CDK9 inhibitor, VIP152, program have been accepted for presentation at the upcoming 63rd American Society of Hematology Annual Meeting, to be held December 11-14, 2021 in Atlanta, GA.

Freeline Therapeutics Holdings plc today announced that data from its long-term follow-up study to its Phase 1/2 B-AMAZE clinical trial of FLT180a for the treatment of hemophilia B will be presented at the 63rd American Society of Hematology

Y-mAbs Therapeutics, Inc. announced that, based on feedback from the U.S. Food and Drug Administration at a recent Type B meeting, where the Company provided the FDA with additional detailed data and the statistical analysis plan, the Company has requested a pre-BLA meeting for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer announced that it will present updated data from its blood cancer portfolio at the 63rd Annual Meeting of the American Society of Hematology taking place December 11 – 14, 2021.

Cybin Inc. today announced that the Company has been granted a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (“DEA”).

IMV Inc. today announced that it will hold a conference call and webcast on Thursday, November 11, 2021 at 8:00 a.m. ET to discuss the company’s third quarter 2021

AVROBIO, Inc. today reported financial results for the quarter ended Sept. 30, 2021, and provided a business update.

Ironwood Pharmaceuticals, Inc. today reported financial results for third quarter 2021.

Intellia Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021, and recent operational highlights.